OctoPlus signs drug development contract with The Medicines Company
(Thomson Reuters ONE) -
OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), announces today
that it has signed a pharmaceutical development and manufacturing contract with
a new client, US-based The Medicines Company. The undisclosed contract value
will make a material contribution to OctoPlus' annual revenues.
Under the contract terms, OctoPlus will perform process development and clinical
manufacturing for The Medicines Company related to MDCO-216 (ApoA-I
Milano/phospholipid complex).
OctoPlus provides formulation development and clinical material manufacturing
services to biotech and pharmaceutical companies worldwide. In addition to its
expertise in formulation and manufacturing, OctoPlus offers its clients drug
delivery technologies for the development of controlled release versions of
existing or new drugs.
For further information, please contact:
Rianne Roukema, Corporate Communications: telephone number +31 (71) 524 1071 or
send an e-mail to Investor Relations at IR(at)octoplus.nl.
About OctoPlus
OctoPlus is a drug delivery company committed to the creation of improved
pharmaceutical products that are based on OctoPlus' proprietary drug delivery
technologies and have fewer side effects, improved patient convenience and a
better efficacy/safety balance than existing therapies. OctoPlus focuses on the
development of long-acting, controlled release versions of known protein
therapeutics, other drugs, and vaccines on behalf of its clients.
The clinically most advanced product incorporating our technology is Biolex
Therapeutics' lead product Locteron®, a controlled release formulation of
interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed
Locteron exclusively to Biolex in October 2008. Locteron is being manufactured
for Biolex by OctoPlus and is currently in Phase IIb clinical studies.
In addition, OctoPlus is a leading European provider of advanced drug
formulation and clinical scale manufacturing services to the pharmaceutical and
biotechnology industries, with a focus on difficult-to-formulate active
pharmaceutical ingredients.
OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO.
For more information about OctoPlus, please visit our website www.octoplus.nl.
This document may contain certain forward-looking statements relating to the
business, financial performance and results of OctoPlus and the industry in
which it operates. These statements are based on OctoPlus' current plans,
estimates and projections, as well as its expectations of external conditions
and events. In particular the words "expect", "anticipate", "predict",
"estimate", "project", "plan", "may", "should", "would", "will", "intend",
"believe" and similar expressions are intended to identify forward-looking
statements. We caution investors that a number of important factors, and the
inherent risks and uncertainties that such statements involve, could cause
actual results or outcomes to differ materially from those expressed in any
forward-looking statements. In the event of any inconsistency between an English
version and a Dutch version of this document, the English version will prevail
over the Dutch version.
[HUG#1430917]
Click here for the press release in PDF: http://hugin.info/137076/R/1430917/377483.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: OctoPlus N.V. via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 12.07.2010 - 07:30 Uhr
Sprache: Deutsch
News-ID 23738
Anzahl Zeichen: 0
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 211 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"OctoPlus signs drug development contract with The Medicines Company"
steht unter der journalistisch-redaktionellen Verantwortung von
OctoPlus N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
